Abstract
Despite great advances in understanding the molecular etiology of cancer and neurodegeneration, therapeutic strategies against these diseases are still largely lacking. Hence, acceleration of the discovery of new therapeutic agents against these pathologies is of enormous interest.
This review is focused on the role of multi-faceted and expanding yeast cell-based systems in the search for new drugs and therapeutic targets in cancer and neurodegeneration. Though the obvious limitations of using a microorganism to address human diseases, when used in the early phase and with complementary mammalian systems, it can have a tremendous impact in the discovery of new therapeutic opportunities. In this review, many evidence are provided demonstrating the valuable contribution of yeast in this area. Additionally, several yeast target-based drug screening approaches based on a readily screenable phenotype on genomic technologies increasingly oriented towards genetic and chemical high-throughput analysis are addressed.
Altogether, with this review, we intend not only to recognize previous successes and ongoing work in this area, but also to point out new opportunities that may be of interest for yeast as a model organism and as a powerful system in the discovery of new lead compounds that have the potential to become novel drugs in cancer and neurodegeneration.
Keywords: Yeast, cancer, neurodegeneration, drug discovery, therapeutic targets, target-based screening, genome-wide screening, yeast cell-based systems, microorganism, novel drugs.
Current Pharmaceutical Design
Title:New Therapeutic Strategies for Cancer and Neurodegeneration Emerging from Yeast Cell-based Systems
Volume: 18 Issue: 27
Author(s): Clara Pereira, Mariana Leao, Joana Soares, Claudia Bessa and Lucilia Saraiva
Affiliation:
Keywords: Yeast, cancer, neurodegeneration, drug discovery, therapeutic targets, target-based screening, genome-wide screening, yeast cell-based systems, microorganism, novel drugs.
Abstract: Despite great advances in understanding the molecular etiology of cancer and neurodegeneration, therapeutic strategies against these diseases are still largely lacking. Hence, acceleration of the discovery of new therapeutic agents against these pathologies is of enormous interest.
This review is focused on the role of multi-faceted and expanding yeast cell-based systems in the search for new drugs and therapeutic targets in cancer and neurodegeneration. Though the obvious limitations of using a microorganism to address human diseases, when used in the early phase and with complementary mammalian systems, it can have a tremendous impact in the discovery of new therapeutic opportunities. In this review, many evidence are provided demonstrating the valuable contribution of yeast in this area. Additionally, several yeast target-based drug screening approaches based on a readily screenable phenotype on genomic technologies increasingly oriented towards genetic and chemical high-throughput analysis are addressed.
Altogether, with this review, we intend not only to recognize previous successes and ongoing work in this area, but also to point out new opportunities that may be of interest for yeast as a model organism and as a powerful system in the discovery of new lead compounds that have the potential to become novel drugs in cancer and neurodegeneration.
Export Options
About this article
Cite this article as:
Pereira Clara, Leao Mariana, Soares Joana, Bessa Claudia and Saraiva Lucilia, New Therapeutic Strategies for Cancer and Neurodegeneration Emerging from Yeast Cell-based Systems, Current Pharmaceutical Design 2012; 18 (27) . https://dx.doi.org/10.2174/138161212802430422
DOI https://dx.doi.org/10.2174/138161212802430422 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy EDITORIAL [Hot topic: RAS - A Central Feature in Cancer Targeted Therapy (Guest Editor: Balazs Gyorffy)
Current Cancer Drug Targets A Fatal Case of Acute Interstitial Pneumonia (AIP) in a Woman Affected by Glioblastoma
Current Drug Safety A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas
Current Pharmaceutical Design Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets Reduced Nicotinamide Adenine Dinucleotide (NADH) Fluorescence for the Detection of Cell Death
Anti-Cancer Agents in Medicinal Chemistry Alkylphospholipids are Signal Transduction Modulators with Potential for Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Human Amniotic Fluid Stem Cells as an Attractive Tool for Clinical Applications
Current Stem Cell Research & Therapy Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy HIV-1 Proteins, Tat and gp120, Target the Developing Dopamine System
Current HIV Research Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond
Current Drug Targets Low Concentration of Caffeine Inhibits the Progression of the Hepatocellular Carcinoma <i>via Akt</i> Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Differentiation of High-grade Gliomas from Brain Metastases Using Tissue Similarity Maps (TSMs) Based Relative Cerebral Blood Volume Values
Current Medical Imaging Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Prenylated Xanthones: An Overview
Current Organic Chemistry Alpha-Interferon and Its Effects on Signalling Pathways Within Cells
Current Protein & Peptide Science Subject Index To Volume 12
Current Pharmaceutical Design Natural Compounds Therapeutic Features in Brain Disorders by Experimental, Bioinformatics and Cheminformatics Methods
Current Medicinal Chemistry New Developments in Anti-Angiogenic Therapy of Cancer, Review and Update
Anti-Cancer Agents in Medicinal Chemistry